RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
细胞因子诱导的杀伤（CIK）细胞疗法在结直肠癌中的临床应用：当前策略与未来挑战
英文原题：Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges.
查看英文原题
Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
结直肠癌（CRC）仍然是全球重大的健康负担，是癌症相关死亡的第二大原因。细胞因子诱导的杀伤（CIK）细胞疗法是一种免疫疗法，有潜力满足这一需求。CIK细胞疗法用于CRC管理的临床试验已报告了改善的临床结局。然而，生产和输注方案差异显著，且许多研究仅发表在中文期刊上。在此，我们呈现迄今为止对CIK细胞疗法用于CRC管理临床试验最全面的综述。我们检索了英文和中文的临床研究，并总结了CIK细胞疗法从制造到患者输注的实施方式。我们讨论了当前阻碍CIK细胞疗法在CRC管理中更广泛采用的挑战。
展开英文摘要原文
Colorectal cancer (CRC) remains a significant global health burden and is the second leading cause of cancer-related death. Cytokine induced killer (CIK) cell therapy is an immunotherapy which has the potential to meet this need. Clinical trials of CIK cell therapy for the management of CRC have reported improved clinical outcomes.
However, production and delivery protocols varied significantly, and many studies were reported only in Chinese language journals.
Here we present the most comprehensive review of the clinical CIK cell therapy trials for CRC management to date.
We accessed both English and Chinese language clinical studies, and summarise how CIK cell therapy has been implemented, from manufacturing to patient delivery.
We discuss current challenges that impede wider adoption of CIK cell therapy in CRC management.
论文信息
- 作者
- Ying Li CM、Li R、Drew P、Price T、Smith E、Maddern GJ、Tomita Y、Fenix K
- 第一作者单位
- Department of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA 5005, Australia; Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia.Australia
- 通讯作者单位
- Department of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA 5005, Australia; Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia. Electronic address: kevin.fenix@adelaide.edu.au.Australia
- 文献类型
- 综述
- 期刊
- Cancer treatment reviews2024 Jan
- 原文标识
- PubMed 38091655 · DOI 10.1016/j.ctrv.2023.102665